

2019

Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making

Nathanael Sanchez

Wayne State University, nsanchez@med.wayne.edu

Follow this and additional works at: <https://digitalcommons.wayne.edu/crp>



Part of the [Medical Education Commons](#), and the [Translational Medical Research Commons](#)

Recommended Citation

SANCHEZ N. Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making. Clin. Res. Prac. 2019 Feb 6;5(1):eP1628. doi: 10.22237/crp/1549411200

This Critical Analysis is brought to you for free and open access by the Open Access Journals at DigitalCommons@WayneState. It has been accepted for inclusion in Clinical Research in Practice: The Journal of Team Hippocrates by an authorized editor of DigitalCommons@WayneState.

Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making

NATHANAEL SANCHEZ, Wayne State University School of Medicine, nsanchez@med.wayne.edu

ABSTRACT A critical appraisal and clinical application of Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. *Am J Respir Crit Care Med.* Sep 1 2016;194(5):559-567. doi: [10.1164/rccm.201607-1349OC](https://doi.org/10.1164/rccm.201607-1349OC).

Keywords: Roflumilast, COPD, RE(2)SPOND, corticosteroid

Clinical Context

A 58-year-old female presented with shortness of breath, productive cough, and wheezing for the past two days. She has a past medical history significant for a 30 pack-year smoking history and COPD, which was confirmed with Pulmonary Function Testing at an outside institution. The patient reports frequent hospitalizations, with 7-10 visits to the emergency room and multiple hospitalizations in the past year, all for the same symptoms of shortness of breath, cough, and wheezing.

The patient was admitted for treatment of her COPD exacerbation. Her medications included a Long Acting Beta Agonist (LABA), Long Acting Muscarinic Agonist (LAMA), and inhaled corticosteroid, with an albuterol inhaler as needed. Her acute exacerbation was treated with Duonebs (Ipratropium bromide/albuterol), antibiotics, and prednisone, with resolution of acute symptoms. Her history of frequent COPD exacerbations requiring hospitalization was severely impacting her quality of life, and she wanted to know if there was some way of preventing such frequent hospitalizations. The team debated if roflumilast would decrease her frequency of hospitalizations for COPD exacerbations, as there is conflicting evidence and opinions on the topic.

Clinical Question

Is roflumilast effective in reducing the frequency of COPD exacerbations among patients with COPD despite treatment with inhaled corticosteroid/LABA/LAMA?

NATHANAEL SANCHEZ is a 4th year medical student at Wayne State University School of Medicine.



ISSN: 2379-4550

<http://digitalcommons.wayne.edu/crp/>, © 2019 The Author(s)

Licensed under [Creative Commons Attribution Non-Commercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/)

Research Article

Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. *Am J Respir Crit Care Med.* Sep 1 2016;194(5):559-567. doi: [10.1164/rccm.201607-1349OC](https://doi.org/10.1164/rccm.201607-1349OC)

Related Literature

A search for original studies was done using the keywords “roflumilast” and “copd” in PubMed. For each relevant article found, the references were reviewed for further original research studies that addressed the clinical question. A search including both keywords in the title yielded 57 sources. Of those, 13 were clinical trials.

Of the 13 clinical trials, two pooled data from multiple studies making them not original work appropriate for appraisal in this context.^{1,2} These papers found a possible benefit in decreasing the frequency of COPD exacerbations. Four of the other studies focused on the physiological and functional benefits of roflumilast in improving PFT data or decreasing inflammation, but in doing so do not address the clinical question.³⁻⁶ Three more studies were conducted in patient populations exclusively in Asia, the results of which cannot necessarily be translated to the patient population of my patient.⁷⁻⁹ One study focused on cost effectiveness of roflumilast in Germany, which is neither the patient population nor the clinical question of this appraisal.¹⁰ One study assessed the cardiovascular safety of roflumilast, which again is not included in the clinical question.¹¹ There was no increase in cardiovascular risk found. Two sources remained, both of which were actually study designs.^{12,13} These designs led to the discovery of their corresponding large, multi-centered studies examining the effectiveness of roflumilast in reducing the frequency of COPD exacerbations in patients with frequent COPD exacerbations: “Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial,”¹⁴ and “Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting b2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND): A Randomized Clinical Trial.”¹⁵ Both trials were conducted by the same investigators with similar protocols. The REACT trial showed no benefit with an intention to treat analysis. The RE2SPOND trial was chosen because it contained a larger sample size (2,354 in RE2SPOND versus 1,934 in REACT), but patient application should include information from both these trials.

Critical Appraisal

The RE2SPOND study is a 52-week, multicenter, randomized, double-blind, placebo-controlled, phase 4 trial, which examined the efficacy and safety of roflumilast added to inhaled corticosteroid (ICS)/LABA FDC therapy with or without LAMA. The primary outcome was the rate of moderate or severe COPD exacerbations per participant per year. The authors report that the analysis was done with stratification by LAMA use, but this was not a pre-defined outcome in the ClinicalTrials.gov registry (NCT01443845), making this highly suspicious for data dredging. In addition, this paper was sponsored by a pharmaceutical company and involved the active participation of pharmaceutical personnel, which also occurred in the REACT trial. This is cause for doubting the veracity of these research reports. Patients eligible to participate had to be at least 40 years old, with severe to very severe COPD, chronic bronchitis, had two or more exacerbations and/or hospitalizations in the past year, and were receiving ICS and LABA, with or without LAMA use for the past 3 months or longer. They could not have any changes in their medications throughout the randomization process. Randomization 1:1 ultimately assigned 1,178 participants to the treatment group who received roflumilast in addition to their other controller medications, and 1,176 participants to the group who received a placebo in addition to their other controller medications. The treatment was carried out for 52 weeks, in which time data was collected from all 380 sites across 17 countries, including number of hospitalizations and adverse events. All analyses included the intention to treat population.

Regarding the level of evidence, the RE2SPOND study can be classified as a level 2 study according to the Strength of Recommendation Taxonomy (SORT) guidelines.¹⁶ This is due to the reservation related to the author’s bias described above. Additional strengths of this study include that it is a double-blind study, including concealed allocation, analyzed with the intention-to-treat population, with an adequate size (n=2,354) and follow-up.

In analyzing the effect size, there are a few numbers that are important. First is the relative risk (RR) of moderate to severe COPD exacerbation in the study as a whole, which is 0.92 (95% CI: 0.81-1.04). This means that roflumilast failed to show benefit. Figure 3 in the manuscript is unintelligible.



One strength of this study is that the study design, including primary outcomes, number of patients, and statistical analysis, was published prospectively in August 2016.¹³ This ensures transparency throughout the process, and eliminates the idea of a publication bias, as the methods, analysis, and primary outcomes were put forth before data collection.

Another strength is the foresight evident in the exclusion criteria. Patients were excluded from the study if they had other lung diseases, moderate to severe liver impairment, HIV or hepatitis, asthma, cancer within 5 years, alpha1 antitrypsin deficiency, cardiovascular conditions, elevated QTc, elevated BMI, had used theophylline within 2 weeks, or had pulmonary rehabilitation within 3 months. Any one of these conditions could be a confounding variable, and excluding these patients from consideration in the study was an important step in limiting bias. It does however limit the generalizability of the findings.

Table 1 in the study laid out the results of randomization, including age, sex, race, and BMI. It also included pertinent information like smoking status, cigarette pack-years, COPD grading, functional measures, number of hospitalizations, and LAMA use. All of these measures were very similar between the two groups.

With the level of evidence and strengths of the study in mind, there are still some limitations to the study. The process of patient recruitment was not laid out in detail. Also, a significant difference in drop-out rate was observed in the roflumilast group versus the control group (337 in treatment versus 254 in control). However, the intention-to-treat analysis is an attempt to eliminate this bias. Also, itemization of adverse events, including diarrhea, weight loss, and headache, organized by treatment group in Table 2 further shows transparency as a strength of this study.¹⁵ There is a clinically increased risk of diarrhea in the treatment group.

Another potential bias to consider relates to how this study was funded. Daliresp® is the brand name of Roflumilast, and is owned by the pharmaceutical company AstraZeneca. In the disclosures section of this study design, many of the authors disclose that they have received funds from AstraZeneca.

Clinical Application

The RE2SPOND trial failed to show a decrease in COPD exacerbations within the first year.”¹⁵

The patient described above would have fit in with this trial. She met the requirements of the inclusion criteria and did not meet any exclusion criteria. In fact, she would have fit in the subgroup of patients with more than 3 exacerbations in the year before starting roflumilast, since she had 7-10 in the year prior. Subgroup analysis showed benefit from roflumilast therapy by reducing frequency of hospitalizations. The patient specifically wanted something to decrease her number of hospitalizations; however, we cannot justify a strong recommendation. The patient could trial the drug and see if she experiences any adverse events with the medication, including diarrhea, weight loss, and headache, as these were noted to be significantly higher in patients receiving treatment with roflumilast. This is a good case for shared decision making, given the poor quality evidence available.

Learning points:

1. Roflumilast is an effective pharmacologic option to decrease frequency of hospitalizations for patients with COPD who are already treated with ICS and LABA, with or without LAMA, and who still experience more than 3 hospitalizations in a year.
2. Roflumilast may cause adverse events, including nausea, diarrhea, weight loss, insomnia, and headache.
3. Considering its efficacy and adverse events, joint decision-making and patient education are vital parts of prescribing roflumilast.

References

1. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. *Chest.* May 2013;143(5):1302-1311. doi: [10.1378/chest.12-1489](https://doi.org/10.1378/chest.12-1489)



2. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. *The European respiratory journal*. Sep 2011;38(3):553-560. doi: [10.1183/09031936.00178710](https://doi.org/10.1183/09031936.00178710)
3. Barnes NC, Saetta M, Rabe KF. Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast. *BMC pulmonary medicine*. Jan 31 2014;14:9. doi: [10.1186/1471-2466-14-9](https://doi.org/10.1186/1471-2466-14-9)
4. De Backer W, Vos W, Van Holsbeke C, et al. The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients. *The European respiratory journal*. Aug 2014;44(2):527-529. doi: [10.1183/09031936.00011714](https://doi.org/10.1183/09031936.00011714)
5. O'Donnell DE, Bredenkroter D, Brose M, Webb KA. Physiological effects of roflumilast at rest and during exercise in COPD. *The European respiratory journal*. May 2012;39(5):1104-1112. doi: [10.1183/09031936.00096511](https://doi.org/10.1183/09031936.00096511)
6. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. *Thorax*. Dec 2007;62(12):1081-1087. doi: [10.1136/thx.2006.075937](https://doi.org/10.1136/thx.2006.075937)
7. Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. *Chest*. Jan 2014;145(1):44-52. doi: [10.1378/chest.13-1252](https://doi.org/10.1378/chest.13-1252)
8. Lee JS, Hong YK, Park TS, Lee SW, Oh YM, Lee SD. Efficacy and Safety of Roflumilast in Korean Patients with COPD. *Yonsei medical journal*. Jul 2016;57(4):928-935. doi: [10.3349/ymj.2016.57.4.928](https://doi.org/10.3349/ymj.2016.57.4.928)
9. Lee SD, Hui DS, Mahayiddin AA, et al. Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial. *Respirology*. Nov 2011;16(8):1249-1257. doi: [10.1111/j.1440-1843.2011.02038.x](https://doi.org/10.1111/j.1440-1843.2011.02038.x)
10. Nowak D, Ehlken B, Kotchie R, Wecht S, Magnussen H. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany]. *Deutsche medizinische Wochenschrift*. Jan 2013;138(4):119-125. doi: [10.1055/s-0032-1327416](https://doi.org/10.1055/s-0032-1327416)
11. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. *Chest*. Sep 2013;144(3):758-765. doi: [10.1378/chest.12-2332](https://doi.org/10.1378/chest.12-2332)
12. Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. *International journal of chronic obstructive pulmonary disease*. 2012;7:375-382. doi: [10.2147/COPD.S31100](https://doi.org/10.2147/COPD.S31100)
13. Rennard SI, Martinez FJ, Rabe KF, et al. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. *International journal of chronic obstructive pulmonary disease*. 2016;11:1921-1928. doi: [10.2147/COPD.S109661](https://doi.org/10.2147/COPD.S109661)
14. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet*. Mar 7 2015;385(9971):857-866. doi: [10.1016/S0140-6736\(14\)62410-7](https://doi.org/10.1016/S0140-6736(14)62410-7)
15. Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. *Am J Respir Crit Care Med*. Sep 1 2016;194(5):559-567. doi: [10.1164/rccm.201607-1349OC](https://doi.org/10.1164/rccm.201607-1349OC)
16. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *The Journal of the American Board of Family Medicine*. 2004;17(1):59-67. doi: [10.3122/jabfm.17.1.59](https://doi.org/10.3122/jabfm.17.1.59)

